SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle Mexican Grill (CMG) is experiencing significant volatility and negative sentiment following its latest earnings, where reports of slowing customer traffic and stagnant comparable sales disappointed investors. Community discourse is polarized, with many criticizing leadership and rising menu prices, while some traders monitor the stock for potential bounce opportunities or short-squeeze setups amidst the ongoing sector-wide pressure.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as the community highlights its real-world utility, specifically the widespread retail presence of its toys and the potential for upcoming product developments. Investors are actively debating whether to accumulate during the current price consolidation or exercise patience, while drawing parallels between the project's long-term branding strategy and established mainstream media companies.

Ralph Lauren Corp. engages in the design, marketing, and distribution of luxury lifestyle products, including apparel, footwear and accessories, home, fragrances, and hospitality categories. The firm offers products under the brands of Ralph Lauren, Ralph Lauren Luxury, Lauren Ralph Lauren, Polo Ralph Lauren, Lauren Ralph Lauren, Chaps and Hospitality. It operates through the following segments: North America, Europe, and Asia. The North America segment offers Ralph Lauren branded apparel, accessories, home furnishings, and related products made through the retail and wholesale businesses in the U.S. and Canada. The Europe segment includes Ralph Lauren branded products made through the retail and wholesale businesses in Europe and emerging markets. The Asia segment consists of Ralph Lauren branded products made through the retail and wholesale businesses in Asia, Australia, and New Zealand. The company was founded by Ralph Lauren in 1967 and is headquartered in New York, NY.

Ralph Lauren Corp - Ordinary Shares - Class A

Ralph Lauren is attracting significant investor attention as Elliott Wave analysis suggests the stock has entered a powerful Wave III, signaling potential for sustained upward momentum. While some analysts have issued upgrades based on strong brand positioning and pricing power, others advise caution, noting the stock may be overvalued at current levels and pointing to broader sector volatility.

Volkswagen AG engages in the business of developing vehicles and components for the brands of the group. It operates through the following segments: Passenger Cars and Light Commercial Vehicles; Commercial Vehicles; Power Engineering; and Financial Services. The Passenger Cars and Light Commercial Vehicles segment includes developing vehicles, engines, and vehicle software; producing and selling passenger cars and light commercial vehicles; and the corresponding genuine parts business. The Commercial Vehicles segment focuses on trucks, buses, corresponding genuine parts business, and related services. The Power Engineering segment is involved in large-bore diesel engines, turbomachinery, and propulsion components business. The Financial Services segment provides dealer and customer financing, leasing, banking, insurance, and fleet management services. The company was founded on May 28, 1937 and is headquartered in Wolfsburg, Germany.

Volkswagen AG - ADR

Volkswagen is trending as investors and the community closely monitor its massive $5.8 billion joint venture with Rivian, intended to revitalize software capabilities and electrical architecture. Meanwhile, broader sentiment remains cautious due to significant cost-cutting measures, potential plant closures in Germany, and intensifying competition from domestic Chinese EV manufacturers.

The Cosmos network consists of many independent, parallel blockchains, called zones, each powered by classical Byzantine fault-tolerant (BFT) consensus protocols like Tendermint. Some zones act as hubs with respect to other zones, allowing many zones to interoperate through a shared hub. The architecture uses classic BFT and Proof-of-Stake algorithms, instead of Proof-of-Work. Cosmos can interoperate with multiple other applications and cryptocurrencies, something other blockchains can’t do well. By creating a new zone, you can plug any blockchain system into the Cosmos hub and pass tokens back and forth between those zones, without the need for an intermediary.  While the Cosmos Hub is a multi-asset distributed ledger, there is a special native token called the atom. ATOM have three use cases: as a spam-prevention mechanism, as staking tokens, and as a voting mechanism in governance.  As a spam prevention mechanism, ATOM are used to pay fees. The fee may be proportional to the amount of computation required by the transaction, similar to Ethereum’s concept of “gas”. Fee distribution is done in-protocol and a protocol specification is described here.  As staking tokens, ATOM can be “bonded” in order to earn block rewards. The economic security of the Cosmos Hub is a function of the amount of ATOM staked. The more ATOM that are collateralized, the more “skin” there is at stake and the higher the cost of attacking the network. Thus, the more ATOM there are bonded, the greater the economic security of the network.  Atom holders may govern the Cosmos Hub by voting on proposals with their staked ATOM.

Cosmos

Cosmos (ATOM) is trending as the community debates its long-term viability and tokenomics amid a broader discussion on the future of the Inter-Blockchain Communication (IBC) protocol. Investors are actively sharing polarized perspectives, with some highlighting the potential of the Cosmos ecosystem's interoperability and staking rewards, while others express frustration over recent price performance and skepticism regarding its competitive position against other layer-1 networks.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Canton is gaining significant traction as investors highlight growing institutional adoption, including high-profile partnerships with major financial firms and infrastructure providers. The community is actively discussing the network's role in tokenized asset settlement, the recent validator lock-up requirements, and its expanding presence on major exchanges.

Portillo's, Inc. serves street food through high-energy, multichannel restaurants designed to ignite the senses and create a memorable dining experience. The company was founded on June 8, 2021 and is headquartered in Oak Brook, IL.

Portillos Inc - Ordinary Shares - Class A

Portillo's is trending as investors debate whether the current price represents an extreme value opportunity or a persistent downtrend, fueled by speculation regarding a long-overdue CEO hire and high-traffic store openings in new markets like Georgia. Despite strong brand loyalty and packed locations, the community remains divided between those aggressively averaging down in anticipation of a potential short squeeze or buyout, and those frustrated by consistent valuation compression and management's expansion execution.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending as a high-conviction breakout candidate following a robust quarterly earnings beat that surpassed analyst expectations for both revenue and EPS. Investors are actively discussing the company's raised guidance and surging global procedure volumes, with community sentiment shifting toward bullish technical setups and long-term robotic surgery adoption.

Virtuals Protocol is a launchpad platform launched in 2024 that enables users to create, tokenize, and monetize AI agents for gaming, entertainment, and virtual environments without requiring technical expertise. Initially built on Ethereum's Base Layer 2 network, the protocol has expanded to Ethereum mainnet, Solana, and Ronin as of 2025. VIRTUAL serves as the base liquidity pair and transactional currency for all AI agent interactions across the ecosystem.  The protocol operates through a bonding curve system where new AI agents are created with a 100 VIRTUAL fee. Users can buy and sell agent tokens until the agent reaches 42,000 VIRTUAL, at which point it graduates to a permanent liquidity pool paired with VIRTUAL. AI agents are multimodal, capable of text, speech, and 3D animation, and can manage on-chain wallets autonomously. Notable examples include Luna, an AI girl band vocalist with over 500,000 TikTok followers. The GAME framework powers agent functionality, enabling them to process inputs, generate responses, and remember past interactions.  Virtuals Protocol was founded by Jansen Teng and Weekee Tiew, evolving from PathDAO, a gaming guild established in 2021 that pivoted to AI agents in January 2024. The team raised $16 million in seed funding led by DeFiance Capital and Beam. In 2025, major partnerships were announced with Animoca Brands and a collaboration with Zyfai and BasisOS to launch an Agentic Fund of Funds.  Users can stake VIRTUAL tokens for veVIRTUAL to participate in DAO governance and may receive airdrops of agent tokens. When users interact with agents, they pay fees in VIRTUAL that generate protocol revenue. This revenue funds periodic buybacks and burns of the VIRTUAL token, reducing its total supply as a value-accrual mechanism for holders.

Virtual Protocol

Virtual Protocol is currently a major focus for traders as the community intensely debates its long-term potential in the Agentic AI sector, with many highlighting recent integrations and AI-focused developments as catalysts for future growth. While some investors view the asset as a high-conviction 'sleeping giant' primed for an explosive cycle, others remain skeptical, frequently dismissing the price action as a pump-and-dump cycle or expressing frustration over its persistent volatility.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing intense investor focus as the market anticipates an earnings report that could validate its pivot to the AI infrastructure space. The community is closely watching for evidence of high-volume production orders from major hyperscalers, with many investors betting that the companys wafer-level testing technology will become a mandatory choke point for AI chip production.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Small-Cap Trade Shows Signs Of Life: Investors Add $1.7 Billion To IWM In One Day

iShares Russell 2000 ETF saw $1.7 billion inflow on April 1. This suggests growing interest after a volatile period, but not a full shift in leadership yet.read more...

Best-Performing Leveraged ETFs of March 

War-driven volatility crushed global markets in March, but leveraged ETFs surged. Oil, VIX, and inverse plays dominated the winners' list.



<ul class="summary-bullets"><li>Q4 revenue also fell well short of $555.4 million average revenue projection by the analysts.&nbsp;</li><li>PLAY expects to deliver an increase in same store sales, revenue, adjusted core profit and to generate more than $100 million in free cash flow.</li><li>The company opened two new stores in the fourth quarter for a total of 11 new stores in fiscal 2025.</li></ul>Dave &amp; Buster’s (PLAY) shares garnered investors’ attention and fell 3% during Tuesday’s extended hours of trading as it reported lower fourth quarter revenue.&nbsp;PLAY’s Q4 revenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024. It also fell well short of $555.4 million average revenue projection by the analysts.&nbsp;It also swung to loss during Q4 as it reported adjusted net loss of $12.0 million, or $0.35 per diluted share, compared with an adjusted net income of $25.3 million, or $0.66 per diluted share in the fourth quarter of fiscal 2024.The company opened two new stores in the fourth quarter for a total of 11 new stores in fiscal 2025. PLAY said that it also remodeled 16 Dave &amp; Buster’s stores in fiscal 2025, bringing the grand total to 51 recently remodeled Dave &amp; Buster’s stores since this remodel program began in the second half of fiscal 2023.It also ended the fourth quarter of fiscal 2025 with $482.9 million of liquidity, which included $16.6 million in cash and $466.3 million available under its $650.0 million revolving credit facility, net of letters of credit.&nbsp;<h2 class="st-heading-2">Outlook</h2>PLAY expects to deliver an increase in same store sales, revenue, adjusted core profit and to generate more than $100 million in free cash flow.“In 2026, we will make meaningful improvements to the business, sharpening our marketing to drive brand consideration, refining our pricing and menu architecture, launching a powerful lineup of culturally relevant new games, and implementing our refreshed remodel program,” said Tarun Lal, Chief Executive Officer.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around PLAY stock trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen almost 34% so far in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail sentiment around PLAY stock trended in ‘extremely bullish’ territory amid ‘extremely high’ message volume. 

Dave & Buster’s Stock Falls 3% After Q4 Earnings Miss

 PLAY’s Q4 revenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024.

Equity

PLAY’s Q4 revenue of $529.6 million decreased 0.9% from the fourth quarter of fiscal 2024.


<ul class="summary-bullets"><li>The&nbsp;company&nbsp;opened nine new stores and closed five stores during fiscal 2025.</li><li>JILL said that for the first quarter of fiscal 2026, the company expects its net sales to decline 5% to 7% compared to fiscal 2025.</li><li>Jefferies lowered the firm's price target on J.Jill to $14 from $18 and kept a ‘Buy’ rating on the shares.</li></ul>Shares of J. Jill (JILL) slumped 26% on Tuesday after it reported a 3.1% decline in its fourth quarter net sales.&nbsp;Net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million compared to $142.8 million for the fourth quarter of fiscal 2024, it said. Analysts expected revenue of $135.5 million as per data from Stocktwits.&nbsp;JILL reported adjusted net loss per diluted share in the fourth quarter of fiscal 2025 at $0.02 compared to adjusted net income per diluted share of $0.32 in the fourth quarter of fiscal 2024.The company opened nine new stores and closed five stores during fiscal 2025, ending the year with 256 stores compared to 252 stores at the end of fiscal 2024.<h2 class="st-heading-2">Analyst Rationale</h2>Jefferies lowered the firm's price target on J.Jill to $14 from $18 and kept a ‘Buy’ rating on the shares following the company’s earnings report. The analyst told investors in a note that J.Jill delivered Q4 results "above a low bar," but "more importantly" FY26 guidance came in well below Street expectations, driven by cautious demand assumptions and incremental tariff headwinds.BTIG analyst Janine Stichter lowered the firm's price target on J.Jill to $18 from $21 and kept a ‘Buy’ rating on the shares.<h2 class="st-heading-2">Outlook</h2>JILL said that for the first quarter of fiscal 2026, the company expects its net sales to decline 5% to 7% compared to fiscal 2025. Analysts expected revenue for the quarter at $155.65 million, as per Stocktwits.&nbsp;For the full year of fiscal 2026, the company expects net sales to be flat to down 2% compared to fiscal 2025.JILL said that the outlook assumes an average 20% reciprocal tariff rate on applicable inventory received prior to February 28, 2026, an average 10% reciprocal tariff rate on applicable inventory received after February 28, 2026 through the first quarter of fiscal 2026, and an average 15% reciprocal tariff rate thereafter.&nbsp;<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around JILL trended in ‘bullish’ territory amid ‘high’ message volume.&nbsp;Shares in the company are down 19% so far in 2026.&nbsp;&nbsp;

BTIG analyst Janine Stichter lowered the firm's price target on J.Jill to $18 from $21 and kept a ‘Buy’ rating on the shares.

J. Jill Stock Slumps 26% Today – Why Such A Selloff?

JILL’s net sales for the fourth quarter of fiscal 2025 decreased 3.1% to $138.4 million year-over-year. 

<ul class="summary-bullets"><li>BlackSky stated that this contract is aimed at helping with the design and development of next-generation space intelligence.</li><li>CEO Brian O’Toole noted that these developments will enable ultra-high-resolution imaging, enhanced collection performance, and low-latency space-based communications.</li><li>BlackSky said the satellites will serve multiple roles, including acting as data storage and processing hubs and integrating with on-orbit data centers.</li></ul>BlackSky Technology Inc. (BKSY) on Tuesday announced that it has won a U.S. government contract for designing technology for Earth observation.The company stated that the contract’s value is $99 million, slightly lower than BlackSky’s full-year 2025 revenue of $107 million. BlackSky also added that it has already received an initial payment of $2 million.<a href="https://stocktwits.com/symbol/BKSY">BlackSky shares</a> were up nearly 9% in Tuesday morning’s trade. Retail sentiment on Stocktwits around the company trended in the ‘bullish’ territory at the time of writing, with message volumes at ‘extremely high’ levels.<h2 class="st-heading-2">Developing Next-Gen Space Intelligence</h2>BlackSky stated that this contract is aimed at helping with the design and development of next-generation space intelligence. It added that the capabilities and mission applications this project addresses are distinct from those addressed by current Gen-2 and Gen-3 monitoring systems and the company’s future AROS broad-area search system.“We will leverage the unique, highly scalable core technology of Gen-3 into every incremental advancement along our roadmap, looking at the AROS broad area search system as the next step into the more expansive very large-aperture optical imagery capabilities covered by this contract,” said BlackSky CEO Brian O’Toole.He added that these developments will enable ultra-high-resolution imaging, enhanced collection performance, and low-latency space-based communications.The company expects the contract to enable expanded applications in high-cadence Earth monitoring and tracking objects across low Earth, geostationary, and cis-lunar orbits.<h2 class="st-heading-2">Satellites With Multi-Role Capabilities</h2>BlackSky noted that the satellites that will be developed under this contract will serve multiple roles. This includes operating as a data storage and processing hub and being compatible with on-orbit data centers.The company noted that this is an indefinite-delivery, indefinite-quantity contract for a multi-year period.BlackSky is a Herndon, Virginia-based company that provides real-time space intelligence with on-demand imagery, analytics, and high-frequency monitoring of critical global assets and events.<a href="https://stocktwits.com/symbol/BKSY">BKSY stock</a> is up 24% year-to-date and 202% over the past 12 months. The Vanguard Total Stock Market Index Fund ETF (VTI) is up 15% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 22%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warren-buffett-sold-apple-shares-too-soon-berkshire/cZEPvVFRIVi">Buffett Says He Sold Apple Shares Too Soon, But Does Not Regret It: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BlackSky Technology logo is seen displayed on a smartphone screen.

BKSY Stock Is Rising Today – This Government Deal Could Be A Turning Point

BlackSky Technology (BKSY) stated that the contract’s value is $99 million, slightly lower than BlackSky’s full-year 2025 revenue of $107 million.

The company stated that the contract’s value is $99 million, slightly lower than BlackSky’s full-year 2025 revenue of $107 million.

<ul class="summary-bullets"><li>In connection with the transaction, Repay has received a debt commitment letter from Truist Bank for a $500 million term loan, along with a $100 million undrawn revolving credit facility.&nbsp;</li><li>RPAY expects the transaction to close in the second quarter of 2026.</li><li>It expects the transaction to unlock additional value with expected revenue opportunities of approximately $5+ million by 2028.</li></ul>Repay Holdings (RPAY), a provider of integrated payment processing solutions, on Monday announced a definitive agreement to acquire Kubra Data Transfer for approximately $372 million in an all-cash transaction.&nbsp;The company said that the acquisition will be financed with a combination of cash on hand and debt financing.Shares in the company fell nearly 1% during extended hours of trading on Monday.&nbsp;<h2 class="st-heading-2">More Details</h2>In connection with the transaction, RPAY has received a debt commitment letter from Truist Bank for a $500 million term loan, along with a $100 million undrawn revolving credit facility.&nbsp;Repay said that the deal is expected to generate approximately $15+ million of annual run-rate costs synergies and approximately $5+ million of technology savings over the next three years through combining operations, platform consolidation, and other scale efficiencies.&nbsp;“Today’s announcement advances REPAY on our transformational journey to become a leading bill payment provider. The combination brings together highly complementary go-to-market approaches, creating robust opportunities to enhance growth,” said John Morris, Co-Founder and Chief Executive Officer of Repay.The transaction is subject to regulatory approvals in the U.S. and Canada and certain customary closing conditions. The company expects the transaction to close in the second quarter of 2026.<h2 class="st-heading-2">Expected Gains</h2>Repay expects the transaction to unlock additional value with expected revenue opportunities of approximately $5+ million by 2028 as RPAY benefits from offering bill presentment, communications services, a payment engine, and core processing solutions across all clients.It also expects free cash flow accretion of 25% by 2028.<h2 class="st-heading-2">Retail Reaction</h2>Retail sentiment around RPAY stock trended in ‘neutral’ territory amid ‘normal’ message volume.&nbsp;Shares in the company have fallen around 15% so far this year.

Retail sentiment around RPAY stock trended in ‘neutral’ territory amid ‘normal’ message volume. 

Repay Stock Falls As $372M Deal Fails To Impress Investors

The company said that the acquisition will be financed with a combination of cash on hand and debt financing.

<ul class="summary-bullets"><li>Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC&nbsp;reported, citing data from Argus.&nbsp;</li><li>Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28.</li></ul>JetBlue Airways (JBLU) is reportedly raising bag fees for its flyers as rising fuel prices due to the ongoing Iran war begin to&nbsp;weigh on the company.“As we experience rising operating costs, we regularly evaluate how to manage those costs while keeping base fares competitive and continuing to invest in the experience our customers value,” JetBlue said in a statement to CNBC.Fuel prices for Chicago, Houston, Los Angeles and New York averaged $4.57 a gallon last Friday, up nearly 83% since the day before the war began, CNBC reported, citing data from Argus.&nbsp;Airfares have increased globally since the U.S. and Israel’s attack on Iran on Feb. 28. The recent rise in checked bag fees is the latest indication that airlines are passing higher fuel costs onto American travelers. After labor, jet fuel is the largest expense for airlines.<h2 class="st-heading-2">Rising Fuel Prices&nbsp;</h2>Crude oil jumped on Monday and stayed well above $100 a barrel mark, signalling a prolonged Iran war.&nbsp;Benchmark U.S. oil futures gained $3.24 a barrel Monday to settle at $102.88, their first close above $100 since 2022 when Russia invaded Ukraine and rattled energy markets, as per Wall Street Journal.&nbsp; Brent crude futures for May delivery were as high as $116 Monday.&nbsp;The United States Oil Fund ETF (USO) closed 4.5% higher on Monday, while the ProShares Ultra Bloomberg Crude Oil ETF (UCO) ended the day 1.7% higher.&nbsp;<h2 class="st-heading-2">Retail reaction</h2>Retail sentiment around JBLU&nbsp;stock trended in ‘bullish’ territory amid ‘extremely high’ message volume.&nbsp;Shares in the company have fallen around 10% so far this year.&nbsp;

JetBlue Airbus A321neo passenger aircraft spotted departing from the runway of Amsterdam Schiphol Airport in the Netherlands on April 10, 2025.

JetBlue Airways Reportedly Raises Baggage Fees As Rising Fuel Costs Bite

 As JetBlue experiences rising operating costs, it regularly evaluates how to manage those costs while keeping base fares competitive, the airline told CNBC in a statement. 

<ul class="summary-bullets"><li>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging.</li><li>The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.</li><li>Viridian stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter of 2026.</li></ul>Viridian Therapeutics Inc. (VRDN) shares tanked more than 41% in Monday’s pre-market trade after the company announced results from its Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease.Viridian stated that the REVEAL-1 trial of Elegrobart met its primary endpoint of proptosis responder rate (PRR) with a highly statistically significant treatment effect in the four-week dosing regimen.However, the company stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/VRDN">Viridian Therapeutics</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Did The Trial Reveal?</h2>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging. The study also tested a different dosing schedule (every 8 weeks) versus placebo and examined other important outcomes.The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.However, Elegrobart showed only a slight improvement over placebo in the Clinical Activity Score (CAS), a measure of inflammation and disease activity.Viridian’s results showed that the CAS reduction to 0 or 1 was 57% in the four-week regimen and 69% in the eight-week regimen, compared with 50% in the placebo group.The company said that all complaints of adverse events in both regimens were reports of tinnitus, none of which were associated with hearing reduction.<h2 class="st-heading-2">Viridian Says Elegrobart On Track For BLA Submission In 2027</h2>The company stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter (Q2) of 2026.Following this, Viridian plans to submit a Biologics License Application (BLA) to the U.S. FDA in Q1 2027. A BLA is a formal request submitted to the U.S. Food and Drug Administration (FDA) asking for approval to sell a biologic drug.<a href="https://stocktwits.com/symbol/VRDN">VRDN stock</a> is down 12% year-to-date, but up 87% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 40% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 19%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/roma-stock-soars-100m-share-repurchase-program/cZERVIhRIZs">ROMA Stock Shot Up 10% Today – Everything To Know About Its Gigantic Share Repurchase Program</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal?

Viridian stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.

<ul class="summary-bullets"><li>Tonix is now evaluating its Tonmya drug for the treatment of major depressive disorder and acute stress disorder/acute stress reaction.&nbsp;</li><li>The company also expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease.</li><li>According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’.</li></ul>Shares of Tonix Pharmaceuticals (TNXP) fell for the fourth consecutive day on Friday but stayed on the radar of retail investors on Stocktwits who gauged the company’s drug pipeline.Retail chatter around the stock rose 92% over the past 24 hours. Overall, retail sentiment around the stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A user said that the company should cut spending and focus resources on expanding the indication for the company’s FDA-approved drug Tonmya.<stembedurl>https://www.stocktwits.com/ByBi/message/648804308</stembedurl>Another user voiced optimism for the company’s Tonmya drug but noted that the stock is “super diluted.”<stembedurl>https://www.stocktwits.com/BlakeCanyon50/message/648764035</stembedurl>Yet another user voiced optimism for good news while adding that they think it is “very close.”<stembedurl>https://www.stocktwits.com/pickles14/message/648794046</stembedurl><h2 class="st-heading-2">Drug Approvals</h2>The U.S. Food and Drug Administration approved Tonix’s Tonmya for the management of fibromyalgia in adults in August. The non-opioid drug launched in November and through Feb. 27, more than 1,500 healthcare providers prescribed it to patients. About 2,500 patients have initiated treatment with Tonmya, the company said earlier this month.The company is now evaluating the potential of the drug in treating major depressive disorder and acute stress disorder/acute stress reaction.<h2 class="st-heading-2">Other Pipeline Updates</h2>Tonix expects to initiate a U.S. field study in 2027 for its experimental drug TNX-4800 for seasonal prevention of Lyme disease. There are no FDA-approved vaccines or prophylactics for the disease now.Other candidates in its pipeline include TNX-2900 for the treatment of Prader-Willi syndrome, TNX-1500 for the prevention of kidney transplant rejection, and TNX-1900 for the treatment of migraines.According to data from Koyfin, both analysts covering TNXP rate it a ‘Buy’. The 12-month average price target on the stock is $54.33, representing a potential upside of about 322%.<a href="https://stocktwits.com/symbol/TNXP">TNXP stock</a> has dropped 52% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK">ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tonix Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TNXP Stock Dives For Four Straight Sessions — Retail Eyes Drug Pipeline Payoff

On Stocktwits, retail chatter around the stock rose 92% over the past 24 hours as users contemplated on the company’s approved drugs and investigational therapy candidates. 

<ul class="summary-bullets"><li>The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval.</li><li>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company.</li><li>LifeSci Capital added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval.</li></ul>&nbsp;Shares of Rocket Pharmaceuticals Inc. (RCKT) dropped 22% on Friday after the company announced U.S. Food and Drug Administration's approval for its drug in the treatment of an inherited pediatric disorder, a sell-off that Wall Street dismissed as unjustified.Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with severe leukocyte adhesion deficiency-I, an ultra-rare, inherited pediatric immunodeficiency characterized by recurrent, severe infections.The company also said that the FDA granted the company a Rare Pediatric Disease Priority Review Voucher (PRV) following the approval. The voucher is designed to encourage the development of therapies for rare pediatric disease<h2 class="st-heading-2">Wall Street Weighs In</h2>Wedbush reiterated an ‘Outperform’ rating and $16 price target on Rocket Pharmaceuticals, saying the Kresladi approval is a "significant milestone" for the company, which the firm believes reflects management's strong execution. Payer coverage should not be an issue, and the priority review voucher will strengthen Rocket's balance sheet, the analyst told investors in a research note. The firm added that it does not see the negative stock price reaction as justified.LifeSci Capital analyst Patrick Dolezal also reiterated an ‘Outperform’ rating and $9 price target on Rocket Pharmaceuticals. The firm said the PRV could be a potentially meaningful source of non-dilutive capital that could net Rocket $100 million to $200 million. The firm added that it is impressive Rocket was able to usher Kresladi through a complex cell-based gene therapy approval and expects read-through to the company's cardiac gene-therapy pipeline.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around RCKT stock stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/RCKT">RCKT stock</a> has fallen 53% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-model-y-3-deliveries-critical-as-model-s-x-approach-retirement-says-analyst/cZ3HJsGRIm9">Watch Tesla Model Y/3 Q1 Delivery Numbers Closely — Analyst Warns As S/X Near End Of Production</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In the wake of OWL's redemption restrictions, Senator Elizabeth Warren called for tighter oversight of private credit.

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Earlier on Friday, Rocket announced that the FDA has approved its gene therapy Kresladi for the treatment of certain pediatric patients with an ultra-rare immune disorder.

iShares Trust - iShares Russell 2000 ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

Stocktwits

Stocktwits Polls

iShares Russell 2000 ETF

Rising tensions and uncertainty regarding the Iran conflict and Hormuz Strait are driving market-wide volatility and anxiety.

Investors are closely monitoring surging crude prices and their inflationary impact on the broader equity markets.

Traders are intensely watching the Russell 2000 for signs of relative strength, distribution, or a potential broader market reversal.

Technically focused traders are emphasizing pivot points, horizontal support/resistance levels, and renko systems to navigate the current choppy price action.

IWM
iShares Russell 2000 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWM News

IWMiShares Russell 2000 ETF